Document is current
Any future updates will be listed below
-
Authors
Covés-Datson, Evelyn M.
King, Steven R.
Legendre, Maureen
Swanson, Michael D.
Gupta, Auroni
Claes, Sandra
Meagher, Jennifer L.
Boonen, Arnaud
Zhang, Lihong
Kalveram, Birte
Raglow, Zoe
Freiberg, Alexander N.
Prichard, Mark
Stuckey, Jeanne A.
Schols, Dominique
Markovitz, David M.
-
Funding
Funding for this research was provided by:
National Institutes of Health (T32 GM07863)
National Institutes of Health (P30 CA046592)
National Institute of Allergy and Infectious Diseases (1F31AI136615-01)
Michigan Economic Development Corporation and Michigan Technology Tri-Corridor (085P1000817)
U.S. Department of Energy (DE-AC02-06CH11357)
Defense Threat Reduction Agency (HDTRA1-15-1-0067)
Michigan Translational Research and Commercialization (MTRAC) Life Sciences
- License Information
-
More Information
Article History
Received: 15 August 2020
Accepted: 21 December 2020
First Online: 12 January 2021
Competing interests
: D.M.M. and M.D.S. are inventors on patents for H84T BanLec. D.M.M. is a founder of Defense Biosciences, a company that aims to commercialize H84T BanLec. The other authors have no competing interests to declare.
